A New Chapter for Biotechnology Innovation
Artificial intelligence is transforming drug discovery, but the development of new medicines still depends on something fundamental: reliable biological information.
Researchers need to understand how cells respond to genetic changes, experimental treatments, and different biological conditions.
Generating that information can be expensive and technically challenging, particularly when scientists work with limited quantities of patient-derived cells.
Biotechnology startup DropGenie is developing technology intended to address these challenges.
On October 26, 2026, the Montreal- and Boston-based company announced that its Seed+ financing totaled $5 million, with BDC Thrive Venture Fund participating alongside Skeleton Key and other investors.
The announcement adds important details to a financing round DropGenie originally disclosed in June 2026.
The company plans to use its financial backing to expand commercialization of its laboratory automation platform and support partnerships that generate standardized biological datasets.
What Does DropGenie Do?
DropGenie develops technology that miniaturizes gene-editing experiments.
Its platform uses microfluidics, a field involving the controlled movement of extremely small quantities of liquid.
By conducting experiments at a smaller scale, researchers can potentially reduce the biological material and laboratory reagents required.
This is particularly important when working with primary cells obtained directly from patients.
Unlike some laboratory-grown cell lines, primary cells may better reflect the biological characteristics scientists want to study.
However, they can be difficult to obtain in large quantities.
According to DropGenie, its technology can support certain experimental workflows using up to 100 times fewer cells than conventional approaches.
The company is developing applications across functional genomics, cell therapy, and drug discovery.
Its goal is to make experiments involving scarce biological materials more practical and scalable.
Why Biological Data Matters for Artificial Intelligence
AI systems used in biotechnology depend on the quality and relevance of their training and evaluation data.
Researchers can use machine learning to investigate patterns in biological information, but computational predictions still require experimental validation.
For example, an AI model might identify a genetic pathway associated with a disease.
Scientists must then investigate whether manipulating that pathway produces the expected biological response.
Experiments involving actual patient-derived cells can help researchers evaluate those questions.
DropGenie’s approach focuses on making these experiments easier to conduct at scale.
The company is also expanding its services and data partnerships, allowing organizations to access experimental capabilities without necessarily operating every process internally.
These developments could help connect laboratory automation with data-driven biological research.
However, the technology’s broader impact will depend on reproducibility, customer adoption, and demonstrated scientific value.
Meet Alison Hirukawa: The Woman Leading DropGenie
At the center of DropGenie’s development is Alison Hirukawa, PhD, Co-founder and CEO.
Hirukawa has a background in biochemistry and leads the company’s efforts to translate specialized laboratory technology into products for pharmaceutical and biotechnology researchers.
Her leadership represents an important intersection of scientific expertise and entrepreneurship.
Building a biotechnology company requires more than developing a promising laboratory method.
Founders must also navigate product development, manufacturing, fundraising, partnerships, and commercialization.
In DropGenie’s case, that means working to make sophisticated gene-editing technology accessible to research organizations with different technical requirements.
Hirukawa’s role demonstrates how women scientists can help shape the commercial technologies that support future research.
Women Investors Supporting the Next Generation of Biotechnology
DropGenie’s latest announcement also highlights two women venture capital leaders.
Mona Minhas, Managing Partner of BDC Thrive Venture Fund, represents an investment organization focused on supporting women-led Canadian technology companies.
The fund’s participation provides DropGenie with an investor whose mandate includes helping women entrepreneurs build and scale technology businesses.
Ann Lai, Managing Partner of Skeleton Key, is another investor connected to the financing.
Skeleton Key focuses on science-driven technologies that can improve research and development.
The participation of these investors highlights the importance of venture capital in helping scientific innovations progress from laboratory development toward commercialization.
It also demonstrates how women can influence technology innovation from multiple positions: as founders, executives, investors, and strategic decision-makers.
The Business of Scaling Scientific Innovation
DropGenie’s financing announcement identifies several areas of expansion.
The company is working to commercialize its first product, expand access to its experimental capabilities, and develop partnerships involving biological data.
Its approach includes supporting customers that operate the technology in their own laboratories, as well as organizations interested in research services or strategic data partnerships.
These different models may allow DropGenie to serve customers with varying laboratory infrastructure and research needs.
The company says its technology is already being integrated into workflows at major pharmaceutical, biotechnology, and research organizations.
Those statements describe company-reported commercial progress rather than independently established outcomes across the industry.
As DropGenie expands, its ability to deliver consistent results and integrate with existing laboratory systems will be important.
Career Opportunities at the Intersection of AI and Biotechnology
The growth of laboratory automation and AI-enabled drug discovery creates opportunities across several STEM disciplines.
Molecular biologists investigate cellular processes and genetic mechanisms.
Bioengineers develop technologies that connect biological systems with engineered devices.
Software engineers build applications that control laboratory instruments and manage experimental information.
Data scientists help analyze biological datasets and develop computational tools.
Product managers translate scientific requirements into practical technology solutions.
Business development professionals build partnerships with research organizations and pharmaceutical companies.
These roles illustrate the interdisciplinary nature of modern biotechnology.
For women pursuing STEM careers, the field offers opportunities to combine scientific knowledge with engineering, technology, entrepreneurship, and commercial leadership.
Looking Ahead
DropGenie’s $5 million Seed+ financing provides additional support as the company works to commercialize its laboratory automation technology.
The involvement of BDC Thrive Venture Fund also highlights growing investment attention toward women-led technology companies.
For the biotechnology industry, the company’s development reflects increasing interest in generating biological data more efficiently.
For women in STEM, Alison Hirukawa’s leadership offers an example of how scientific expertise can become the foundation of an entrepreneurial venture.
And with investors including Mona Minhas and Ann Lai supporting the company, DropGenie’s story demonstrates how women are contributing to innovation across both scientific research and venture capital.
Sources & Further Reading
- DropGenie — October 26, 2026 financing announcement
- DropGenie — June 22, 2026 Seed+ announcement
- DropGenie — Official website
Discover more from Fems in STEM
Subscribe to get the latest posts sent to your email.
